|
|
Volumn 58, Issue 3, 2011, Pages 151-153
|
|
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer
|
|
Author keywords
Differentiated thyroid carcinoma; Kinase inhibitors; Medullary thyroid carcinoma; Molecularly targeted drugs
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
AXITINIB;
B RAF KINASE;
GEFITINIB;
IMATINIB;
MOTESANIB;
PAZOPANIB;
PLACEBO;
PLATELET DERIVED GROWTH FACTOR RECEPTOR;
PROTEIN RET;
RADIOACTIVE IODINE;
SORAFENIB;
STEM CELL FACTOR RECEPTOR;
SUNITINIB;
SUO 11248;
THYROTROPIN;
UNCLASSIFIED DRUG;
VANDETANIB;
VASCULOTROPIN RECEPTOR;
XL 184;
ADVANCED CANCER;
ANOREXIA;
CANCER SURVIVAL;
DIARRHEA;
DIFFERENTIATED THYROID CARCINOMA;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
DRUG WITHDRAWAL;
FATIGUE;
HUMAN;
HYPERTENSION;
MOLECULARLY TARGETED THERAPY;
PROGNOSIS;
PROGRESSION FREE SURVIVAL;
REVIEW;
SIDE EFFECT;
SKIN DISEASE;
THYROID CANCER;
THYROID FOLLICULAR CARCINOMA;
THYROID MEDULLARY CARCINOMA;
THYROID PAPILLARY CARCINOMA;
ANILIDES;
BENZENESULFONATES;
DISEASE PROGRESSION;
HUMANS;
MOLECULAR TARGETED THERAPY;
PIPERIDINES;
PROTEIN KINASE INHIBITORS;
PYRIDINES;
QUINAZOLINES;
THYROID NEOPLASMS;
|
|
EID: 79953305352
PISSN: 09188959
EISSN: 13484540
Source Type: Journal
DOI: 10.1507/endocrj.K11E-076 Document Type: Review |
|
Times cited : (7)
|
|
References (9)
|
